These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
297 related articles for article (PubMed ID: 28545019)
1. Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection. Li N; Zhou Z; Li F; Sang J; Han Q; Lv Y; Zhao W; Li C; Liu Z Oncotarget; 2017 Jul; 8(28):46020-46033. PubMed ID: 28545019 [TBL] [Abstract][Full Text] [Related]
2. Elevated serum soluble CD14 levels in chronic HBV infection are significantly associated with HBV-related hepatocellular carcinoma. Li N; Zhu Q; Yang C; Li F; Zhou Z; Lv Y; Sang J; Han Q; Liu Z Tumour Biol; 2016 May; 37(5):6607-17. PubMed ID: 26643893 [TBL] [Abstract][Full Text] [Related]
3. Circulating programmed death-1 as a marker for sustained high hepatitis B viral load and risk of hepatocellular carcinoma. Cheng HY; Kang PJ; Chuang YH; Wang YH; Jan MC; Wu CF; Lin CL; Liu CJ; Liaw YF; Lin SM; Chen PJ; Lee SD; Yu MW PLoS One; 2014; 9(11):e95870. PubMed ID: 25427199 [TBL] [Abstract][Full Text] [Related]
4. PRDM1 levels are associated with clinical diseases in chronic HBV infection and survival of patients with HBV-related hepatocellular carcinoma. Li N; Fan X; Wang X; Deng H; Zhang K; Zhang X; Wang Y; Han Q; Lv Y; Liu Z Int Immunopharmacol; 2019 Aug; 73():156-162. PubMed ID: 31100710 [TBL] [Abstract][Full Text] [Related]
5. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma. Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213 [TBL] [Abstract][Full Text] [Related]
6. Association of PD-L1 gene polymorphisms and circulating sPD-L1 levels with HBV infection susceptibility and related liver disease progression. Xuan Hoan N; Thi Minh Huyen P; Dinh Tung B; Phuong Giang D; Tat Trung N; Tien Sy B; Thi Tuan N; Thi Ngoc Dung D; Reddy Pallerla S; Velavan TP; Hong Bang M; Huu Song L Gene; 2022 Jan; 806():145935. PubMed ID: 34478821 [TBL] [Abstract][Full Text] [Related]
7. Serum pentraxin 3 as a biomarker of hepatocellular carcinoma in chronic hepatitis B virus infection. Deng H; Fan X; Wang X; Zeng L; Zhang K; Zhang X; Li N; Han Q; Lv Y; Liu Z Sci Rep; 2020 Nov; 10(1):20276. PubMed ID: 33219288 [TBL] [Abstract][Full Text] [Related]
8. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma. Chang B; Huang T; Wei H; Shen L; Zhu D; He W; Chen Q; Zhang H; Li Y; Huang R; Li W; Wu P Cancer Immunol Immunother; 2019 Mar; 68(3):353-363. PubMed ID: 30506460 [TBL] [Abstract][Full Text] [Related]
9. Soluble Axl Is a Novel Diagnostic Biomarker of Hepatocellular Carcinoma in Chinese Patients with Chronic Hepatitis B Virus Infection. Song X; Wu A; Ding Z; Liang S; Zhang C Cancer Res Treat; 2020 Jul; 52(3):789-797. PubMed ID: 32138467 [TBL] [Abstract][Full Text] [Related]
10. Serum ESPL1 Can Be Used as a Biomarker for Patients With Hepatitis B Virus-Related Liver Cancer: A Chinese Case-Control Study. Wang R; Zang W; Hu B; Deng D; Ling X; Zhou H; Su M; Jiang J Technol Cancer Res Treat; 2020; 19():1533033820980785. PubMed ID: 33308056 [TBL] [Abstract][Full Text] [Related]
11. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. Finkelmeier F; Canli Ö; Tal A; Pleli T; Trojan J; Schmidt M; Kronenberger B; Zeuzem S; Piiper A; Greten FR; Waidmann O Eur J Cancer; 2016 May; 59():152-159. PubMed ID: 27039170 [TBL] [Abstract][Full Text] [Related]
12. Inter-alpha-trypsin inhibitor heavy chain H4 as a diagnostic and prognostic indicator in patients with hepatitis B virus-associated hepatocellular carcinoma. Noh CK; Kim SS; Kim DK; Lee HY; Cho HJ; Yoon SY; Lee GH; Hyun SA; Kim YJ; Kim HJ; Hwang JA; Ahn SJ; Shin SJ; Lee KM; Yoo BM; Cho SW; Cheong JY Clin Biochem; 2014 Sep; 47(13-14):1257-61. PubMed ID: 24836184 [TBL] [Abstract][Full Text] [Related]
13. microRNA-150: a promising novel biomarker for hepatitis B virus-related hepatocellular carcinoma. Yu F; Lu Z; Chen B; Dong P; Zheng J Diagn Pathol; 2015 Jul; 10():129. PubMed ID: 26215970 [TBL] [Abstract][Full Text] [Related]
14. IL17A gene polymorphisms, serum IL-17A and IgE levels, and hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. Li N; Zhu Q; Li Z; Han Q; Zhang G; Chen J; Lv Y; Xing F; Chen Y; Zeng X; Liu Z Mol Carcinog; 2014 Jun; 53(6):447-57. PubMed ID: 23280722 [TBL] [Abstract][Full Text] [Related]
15. Investigation of serum lncRNA-uc003wbd and lncRNA-AF085935 expression profile in patients with hepatocellular carcinoma and HBV. Lu J; Xie F; Geng L; Shen W; Sui C; Yang J Tumour Biol; 2015 May; 36(5):3231-6. PubMed ID: 25501706 [TBL] [Abstract][Full Text] [Related]
16. Changes in Red Blood Cell Distribution Width is Associated with Liver Function Parameters and Prognosis in Patients with Chronic HBV Liver Disease. Kai Y; Zishu G; Shihe G; Yufeng G; Qiang Z Clin Lab; 2016 Nov; 62(11):2197-2202. PubMed ID: 28164679 [TBL] [Abstract][Full Text] [Related]
17. Optimisation of quantitative miRNA panels to consolidate the diagnostic surveillance of HBV-related hepatocellular carcinoma. Tat Trung N; Duong DC; Tong HV; Hien TTT; Hoan PQ; Bang MH; Binh MT; Ky TD; Tung NL; Thinh NT; Sang VV; Thao LTP; Bock CT; Velavan TP; Meyer CG; Song LH; Toan NL PLoS One; 2018; 13(4):e0196081. PubMed ID: 29672637 [TBL] [Abstract][Full Text] [Related]
18. Circulating level of sPD-1 and PD-1 genetic variants are associated with hepatitis B infection and related liver disease progression. Huyen PTM; Dung DTN; Weiß PJ; Hoan PQ; Giang DP; Uyen NT; Van Tuan N; Trung NT; Velavan TP; Song LH; Hoan NX Int J Infect Dis; 2022 Feb; 115():229-236. PubMed ID: 34910956 [TBL] [Abstract][Full Text] [Related]
19. Soluble human leukocyte antigen-G expression in hepatitis B virus infection and hepatocellular carcinoma. Park Y; Park Y; Lim HS; Kim YS; Hong DJ; Kim HS Tissue Antigens; 2012 Feb; 79(2):97-103. PubMed ID: 22136460 [TBL] [Abstract][Full Text] [Related]
20. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Shen Q; Fan J; Yang XR; Tan Y; Zhao W; Xu Y; Wang N; Niu Y; Wu Z; Zhou J; Qiu SJ; Shi YH; Yu B; Tang N; Chu W; Wang M; Wu J; Zhang Z; Yang S; Gu J; Wang H; Qin W Lancet Oncol; 2012 Aug; 13(8):817-26. PubMed ID: 22738799 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]